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Use of etomidate for anesthesia induction is still
debated. In the previous issue of Critical Care, Heinrich
and colleagues reported that etomidate for anesthesia
induction had similar outcome in comparison with
other drugs, in a specific population of 3,054 patients
ahead of major cardiac surgery. For the authors, the
similar outcomes for mortality and length of hospital
stay add to the hemodynamic stability and the
improved intubation conditions to support keeping
etomidate in the emergency drugs armamentarium
for induction of anesthesia in patients at risk of
hemodynamic failure. This commentary reviews the
results and implications of their study.Introduction
Etomidate is often considered as a two-edged sword and
its use for induction of anesthesia is thus controversial.
On the one hand, etomidate is used for its hemodynamic
stability after anesthesia induction and also allows good
intubation conditions, especially in more severely ill
patients, and on the other it has negative effects on steroid
synthesis. The relative importance of both the positive
and negative effects for outcome of patients in both
anesthesia and/or critical care is, however, a highly contro-
versial issue.
In the previous issue of Critical Care, Heinrich and
colleagues [1] reported in their single monocenter study
that etomidate for anesthesia induction resulted in
similar outcomes to other drugs in a specific population
of 3,054 patients ahead of major cardiac surgery. What
does this study add to what we already know?* Correspondence: s-jaber@chu-montpellier.fr
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study are concordant with the recent study of Wagner and
colleagues [2], a retrospective analysis of 3,127 patients
receiving etomidate or propofol for induction of anesthesia;
no increase was observed in severe hypotension, hospital
mortality, duration of hospital stay, duration of ICU stay
and duration of mechanical ventilation in the etomidate
group. For the authors, this study adds evidence in support
of keeping etomidate in the emergency drugs armamentar-
ium for induction of anesthesia [3-5]. Indeed, when asses-
sing the currently available induction agents for cardiac
anesthesia, none is ideal. An ideal induction agent would
be one that is easy to administer, has rapid on- and offset,
and is devoid of clinically significant hemodynamic side
effects. Currently, such an agent does not exist.Adrenal suppression
Etomidate use for anesthesia induction has been an
important subject of controversy over the past years.
Indeed, it has been well known that adrenal mitochon-
drial 11-β-hydroxylase activity is transiently inhibited by
a single dose of etomidate, with consecutive adrenal sup-
pression [6]. Whether etomidate is associated with impaired
outcome is still debated and differs depending on patient
categories (for example, anesthesia in the operating room,
intensive care, emergency department and prehospital
area). In critically ill patients suffering from sepsis, studies
and meta-analyses found either an increased [7], an equal
[8,9] or a decreased [3] risk of mortality after induction of
anesthesia by etomidate for intubation. In major cardiac
surgery, the clinical relevance of adrenal suppression after
a single dose of etomidate for induction is controversial.
Indeed, to our knowledge, etomidate induction has never
been associated with ‘conclusive’ negative outcome data
[2,10]. Again, in the current study [1], induction with eto-
midate was not associated with worse outcomes in com-
parison with other drugs.entral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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Cardiac surgery and the initiation of cardiopulmonary
bypass are stimulators of the inflammatory response.
Variations in cortisol occur after major cardiac surgery
and because cortisol acts synergistically with endogenous
epinephrine and norepinephrine, the impairment of these
stress hormones after etomidate induction is likely to
contribute to an increase in vasopressor requirement. In
the current study [1], the per-operative vasopressor re-
quirement, Sequential Organ Failure Assessment (SOFA)
score and inflammation blood parameters (C-reactive
protein, procalcitonin and leukocytes) were not signi-
ficantly different between the etomidate and the non-
etomidate groups over the 5-day course observed.
These results do not indicate that adverse events occur
following adrenal suppression induced by etomidate.
Due to the systemic inflammatory response related to
cardiac surgery and the initiation of cardiopulmonary
bypass, some studies provide encouraging evidence that
steroids may impact on clinically important outcomes.
Note that steroid utilization in the perioperative period
was not described in the study of Heinrich and col-
leagues [1].Hemodynamic parameters
Post-induction hypotension has been associated with
increased morbidity and mortality, both in anesthesia
[11] and intensive care [4,12,13]. As an imidazole deriva-
tive, etomidate has structural similarities to α2Β-agonists,
causing peripheral vasoconstriction, which contributes to
the stable hemodynamic profile of this agent. Patients with
cardiovascular compromise may be dependent on a high
sympathetic tone to maintain their systemic vascular re-
sistance, blood pressure, and cardiac output. For pre-
vention of post-induction hypotension or hypertension,
etomidate would appear to be more appropriate than pro-
pofol, thiopental, ketamine, or midazolam. In the current
study [1], there was no difference in vasopressor require-
ment between the groups.Outcome
The similar outcomes observed in this study [1] for
mortality, length of hospital stay, length of ICU stay,
re-admission to ICU, duration of mechanical ventilation
and SOFA score after induction with etomidate in com-
parison with other drugs could be the result of the
opposite effects of hemodynamic stability and adrenal
suppression. Moreover, better intubation conditions
were found in the etomidate group, as already reported
in the literature [14]. Etomidate could be associated
with decreased difficult intubation incidences and com-
plications associated with difficult intubation, even if
not assessed in the study.Limits of the study
Some limits of the study [1] have to be pointed out.
First, the drugs used in the non-etomidate group are not
detailed; neither are incidences of difficult intubation
and associated complications. Second, it was a single
center study, which may limit the generalizability of the
results. Third, all retrospective observational research,
no matter how well adjusted for confounding influences,
is vulnerable to residual confounding. Further random-
ized controlled studies are still needed to better evaluate
the potential unknown confounding factors. For example,
it is unclear if the patients intubated with etomidate were
sicker than the patients intubated with other agents.
Nevertheless, Heinrich and colleagues [1] underline
that etomidate remains one of the rare emergency drugs
available for induction of anesthesia and cannot be aban-
doned in the setting of major cardiac surgery. Other
drugs such as ketamine, thiopenthal or propofol can also
be harmful in the setting of induction of anesthesia ahead
of major cardiac surgery. The risk:benefit ratio of induc-
tion with etomidate should be carefully assessed before
anesthetic induction of cardiac surgical patients, taking
into account the associated conditions and particularly
hemodynamic data. Indeed, major cardiac surgery patients
differ from critically ill septic patients, and etomidate
could be particularly appropriate in this situation.
However, further large randomized clinical trials are
needed to determine if there is any ‘optimal’ induction
drug in major cardiac surgery. Analogues of etomidate,
such as cyclopropyl methoxycarbonyl metomidate [15],
could be of interest to retain the beneficial hemodynamic
effects of etomidate with less impairment of the adrenal
function.Conclusion
There are no convincing or consistent data from evidence-
based medicine that etomidate is associated with poor
outcome, especially increased mortality, particularly if
adjustment is made for pre-existing severity of illness.
Although some authors have suggested that, in the ICU,
physicians should abandon the use of etomidate, the
present study of Heinrich and colleagues [1], performed
in the setting of anesthesia care, adds a new piece in the
‘etomidate puzzle’. Etomidate could be considered as an
interesting and alternative drug in the setting of major
cardiac surgery. Finally, it makes the decision to use or
not use etomidate more and more complex: it should be
used in ways that are adapted to every type of patient
and reason for intubation (including type of surgery).
The story of etomidate is to be continued.Abbreviation
SOFA: Sequential organ failure assessment.
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